Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
acetaminophen, Activin, Adicet, adolescent, Adverum, altogether, analgesic, angina, anthony, antigen, argument, aspect, assign, assignment, ASU, ATTR, background, BAL, Banc, baricitinib, barring, bassler, bilateral, Bio, biotech, Bird, blackmail, BMR, bonnie, Brexit, Brolucizumab, Cabilly, CAF, CAPELLA, carcinoma, chosen, Cinqair, citrate, competitor, complication, concomitant, counterpart, crisaborole, CRL, Curascript, cyclosporine, de, Deutschland, differentiate, disc, DMC, Dupixent, EADV, East, EP, erythema, ESCAPE, ESR, Eucrisa, evidenced, exit, expedited, expert, expiry, Fibrodysplasia, FOP, France, futility, Galderma, gemcabene, Gemphire, grande, Greenburgh, heard, hematologic, hip, HoFH, Hollow, huda, HUMIRA, hyperlipidemia, hypoaesthesia, Immunex, inactivating, ingredient, intangible, Intellia, interchangeable, intravenously, iridocorneal, JAK, judgement, jury, Kevraza, Kevzara, KevzaraTM, kidney, killing, Le, lessee, Lessor, lipase, liver, Lymphoblastic, magazine, McKesson, McMaster, membrane, Memorandum, mental, microvascular, Middle, mild, moot, Mount, mutually, nonsteroidal, NPDR, NSAID, NY, occupy, oldest, Ontario, opioid, optic, outpatient, overwhelming, PANORAMA, panretinal, paper, paraesthesia, pathway, pcJIA, PDUFA, peripheral, permission, pose, predetermined, predominately, proceeding, Progressiva, provisional, PRP, Questionnaire, qw, ranked, ransom, rebalancing, redistribute, reexamination, referendum, regime, rentable, repeal, rest, resubmit, rinucumab, Rock, routine, RUBY, school, SD, simultaneously, Sleepy, sponsorship, stay, stayed, stopped, subpoena, subscale, susceptible, suspend, suspended, Talent, TBA, TCS, tofacitinib, traction, Trait, Transthyretin, treaty, trevogrumab, Tribunal, Troy, undergoing, Unlimited, unplanned, unstable, upheld, verdict, vi, vitrectomy, vivo, Winthrop, WOMAC, Xeljanz, zoghbi
Removed:
Affordable, annum, aptamer, ascertained, averaging, choice, choose, Columbia, copy, counterclaimed, criterion, DARPin, Denmark, desire, distributor, extraordinary, ezetimibe, Fovista, fundamental, genome, geographic, gouty, Idec, incumbent, inhibited, inside, lipid, MONO, MTX, myopia, nausea, occurred, Ophthotech, partially, pathologic, progression, prostate, reaction, receiver, recognizing, recombination, redeem, referenced, renewal, rental, repurchased, reserved, retroactively, shift, skeletal, slightly, survival, takeover, taxpayer, undisclosed, unwind, VENICE, warehousing
Filing tables
Filing exhibits
- 10-K Annual report
- 10.20.4 Goldman Sachs Termination Agreement, by and Between Goldman Sachs and Registrant
- 10.22.3 Citi 3RD Warrant Agreement, by and Between Citi and Registrant
- 10.22.4 Citi Termination Agreement, by and Between Citi and Registrant
- 10.24.5 Credit Suisse Termination Agreement, by and Between Credit Suisse and Registrant
- 10.26.3 Morgan Stanley Termination Agreement, by and Between Morgan Stanley & Registrant
- 10.35 Purchase Agreement, by & Among Bmr-landmark LLC, Bmr-landmark IV LLC, & REGN
- 21.1 Subsidiaries of Regeneron Pharmacuticals, Inc.
- 23.1 Consent of Pricewaterhousecoopers LLP
- 31.1 Certification of CEO Pursuant to Rule 13A-14(A)
- 31.2 Certification of CFO Pursuant to Rule 13A-14(A)
- 32 Certification of CEO and CFO Pursuant to 18 U.s.c. Section 1350
- Download Excel data file
- View Excel data file
Related press release
REGN similar filings
Filing view
External links